Literature DB >> 8877390

Cyclophosphamide-induced immunological tolerance: an overview.

H Mayumi1, M Umesue, K Nomoto.   

Abstract

A cyclophosphamide (CP)-induced tolerance system in mice that primarily consists of donor cell injection followed by CP-treatment was found useful for inducing a long-lasting allo- or xeno-tolerance to various solid organs. In the cells-followed-by-CP system, the sequential mechanisms of tolerance were clarified using the specific correlation between superantigens and certain T cell receptor (TCR) V beta segments. Those include the clonal destruction of antigen-stimulated mature T cells, the peripheral clonal deletion associated with peripheral chimerism, the intrathymic clonal deletion associated with intrathymic chimerism, and the clonal anergy. The generation of suppressor T cells was another important mechanism of tolerance in the late stage. Special care was taken to overcome the " hard" barriers of allo- or xeno-combinations by reducing the "split tolerance" produced through the clonal destruction mechanism. For this purpose, the tolerogen, antimitotic drugs, their doses, timing, route of administration, combined immunosuppressants, and supportive treatment were all crucial for successful induction of a long-lasting skin tolerance. This system may be applicable to human transplantation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877390     DOI: 10.1016/S0171-2985(96)80033-7

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  45 in total

Review 1.  High-dose cyclophosphamide for autoimmunity and alloimmunity.

Authors:  Robert A Brodsky
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

2.  Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.

Authors:  Alessandra Roberto; Luca Castagna; Veronica Zanon; Stefania Bramanti; Roberto Crocchiolo; James E McLaren; Sara Gandolfi; Paolo Tentorio; Barbara Sarina; Inna Timofeeva; Armando Santoro; Carmelo Carlo-Stella; Benedetto Bruno; Cristiana Carniti; Paolo Corradini; Emma Gostick; Kristin Ladell; David A Price; Mario Roederer; Domenico Mavilio; Enrico Lugli
Journal:  Blood       Date:  2015-03-05       Impact factor: 22.113

Review 3.  Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia.

Authors:  Melhem Solh
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

4.  Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes.

Authors:  Yu Wang; Ying-Jun Chang; Lu Chen; Lan-Ping Xu; Zhi-Lei Bian; Xiao-Hui Zhang; Chen-Hua Yan; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Oncoimmunology       Date:  2017-09-14       Impact factor: 8.110

5.  HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation.

Authors:  A Rashidi; J F DiPersio; P Westervelt; C N Abboud; M A Schroeder; I Pusic; A F Cashen; T A Fehniger; R Romee
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

6.  Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections.

Authors:  R V Raj; P Hari; M Pasquini; N Epperla; A D'Souza; T Fenske; B E Shaw; J D Rizzo; W Drobyski; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

Review 7.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

8.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Authors:  Yvette L Kasamon; Leo Luznik; Mary S Leffell; Jeanne Kowalski; Hua-Ling Tsai; Javier Bolaños-Meade; Lawrence E Morris; Pamela A Crilley; Paul V O'Donnell; Nancy Rossiter; Carol Ann Huff; Robert A Brodsky; William H Matsui; Lode J Swinnen; Ivan Borrello; Jonathan D Powell; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-18       Impact factor: 5.742

Review 9.  Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation.

Authors:  Leo Luznik; Paul V O'Donnell; Ephraim J Fuchs
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

10.  Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases.

Authors:  R A Brodsky; L Luznik; J Bolaños-Meade; M S Leffell; R J Jones; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-07-14       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.